{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T05:19:02Z","timestamp":1739423942085,"version":"3.37.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Ministry of Health & Welfare, Republic of Korea","award":["HI23C015100"],"award-info":[{"award-number":["HI23C015100"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-024-06173-1","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T03:08:03Z","timestamp":1735960083000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term clinical outcome of a weekly 2-chlorodeoxyadenosine regimen in treatment-na\u00efve patients with hairy cell leukemia"],"prefix":"10.1007","author":[{"given":"Ye Eun","family":"Oh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gi-June","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Woo","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong Yoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung-Su","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Ho","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung-Sik","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki-Seong","family":"Eom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoo-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee-Je","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok-Goo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,4]]},"reference":[{"key":"6173_CR1","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/ajh.26390","volume":"97","author":"X Troussard","year":"2022","unstructured":"Troussard X, Ma\u00eetre E, Cornet E (2022) Hairy cell leukemia 2022: update on diagnosis, risk-stratification, and treatment. Am J Hematol 97:226\u2013236. https:\/\/doi.org\/10.1002\/ajh.26390","journal-title":"Am J Hematol"},{"key":"6173_CR2","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/blood-2016-01-689422","volume":"129","author":"MR Grever","year":"2017","unstructured":"Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B (2017) Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 129:553\u2013560. https:\/\/doi.org\/10.1182\/blood-2016-01-689422","journal-title":"Blood"},{"key":"6173_CR3","doi-asserted-by":"publisher","first-page":"E116","DOI":"10.1002\/ajh.26881","volume":"98","author":"N Epperla","year":"2023","unstructured":"Epperla N, Zhao Q, Anghelina M, Neal J, Blachly JS, Rogers KA, Lozanski G, Oakes CC, Bhat SA, Zent CS, Banerji V, Grever M, Andritsos LA (2023) Impact of sex on outcomes in patients with hairy cell leukemia. An HCL patient data registry analysis. Am J Hematol 98:E116\u2013E118. https:\/\/doi.org\/10.1002\/ajh.26881","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"6173_CR4","first-page":"57","volume":"14","author":"E Matutes","year":"1994","unstructured":"Matutes E, Morilla R, Owusu-Ankomah K, Houliham A, Meeus P, Catovsky D (1994) The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leuk Lymphoma 14(Suppl 1):57\u201361","journal-title":"Leuk Lymphoma"},{"key":"6173_CR5","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1200\/JCO.2010.31.7016","volume":"29","author":"MR Grever","year":"2011","unstructured":"Grever MR, Lozanski G (2011) Modern strategies for hairy cell leukemia. J Clin Oncol 29:583\u2013590. https:\/\/doi.org\/10.1200\/JCO.2010.31.7016","journal-title":"J Clin Oncol"},{"key":"6173_CR6","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1182\/blood-2016-07-418434","volume":"128","author":"B Falini","year":"2016","unstructured":"Falini B, Martelli MP, Tiacci E (2016) BRAF V600E mutation in hairy cell leukemia: from bench to bedside. Blood 128:1918\u20131927. https:\/\/doi.org\/10.1182\/blood-2016-07-418434","journal-title":"Blood"},{"key":"6173_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3343\/alm.2015.35.2.257","volume":"35","author":"SY Shin","year":"2015","unstructured":"Shin SY, Lee ST, Kim HJ, Ki CS, Jung CW, Kim JW, Kim SH (2015) BRAF V600E and MAP2K1 mutations in hairy cell leukemia and splenic marginal zone lymphoma cases. Ann Lab Med 35:257\u2013259. https:\/\/doi.org\/10.3343\/alm.2015.35.2.257","journal-title":"Ann Lab Med"},{"key":"6173_CR8","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","volume":"364","author":"E Tiacci","year":"2011","unstructured":"Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, Sportoletti P, Pettirossi V, Mannucci R, Elliott O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, Fo\u00e0 R, Farinelli L, Haferlach T, Pasqualucci L, Rabadan R, Falini B (2011) BRAF mutations in hairy-cell leukemia. N Engl J Med 364:2305\u20132315. https:\/\/doi.org\/10.1056\/NEJMoa1014209","journal-title":"N Engl J Med"},{"key":"6173_CR9","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1111\/bjh.18224","volume":"198","author":"MS De Propris","year":"2022","unstructured":"De Propris MS, Musiu P, Intoppa S, Nardacci MG, Pucciarini A, Santi A, Peragine N, Canichella M, De Luca ML, D\u2019Elia GM, Del Giudice I, Pulsoni A, Falini B, Guarini A, Martelli M, Tiacci E, Fo\u00e0 R (2022) Hairy cell leukaemia with low CD103 expression: a rare but important diagnostic pitfall. Br J Haematol 198:e28\u2013e31. https:\/\/doi.org\/10.1111\/bjh.18224","journal-title":"Br J Haematol"},{"key":"6173_CR10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1182\/blood.V61.2.349.349","volume":"61","author":"HM Golomb","year":"1983","unstructured":"Golomb HM, Vardiman JW (1983) Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. Blood 61:349\u2013352","journal-title":"Blood"},{"key":"6173_CR11","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1182\/blood.V68.2.493.493","volume":"68","author":"JR Quesada","year":"1986","unstructured":"Quesada JR, Hersh EM, Manning J, Reuben J, Keating M, Schnipper E, Itri L, Gutterman JU (1986) Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood 68:493\u2013497","journal-title":"Blood"},{"key":"6173_CR12","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1182\/blood.V92.6.1918","volume":"92","author":"A Saven","year":"1998","unstructured":"Saven A, Burian C, Koziol JA, Piro LD (1998) Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 92:1918\u20131926","journal-title":"Blood"},{"key":"6173_CR13","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1182\/blood.V96.1.71","volume":"96","author":"IW Flinn","year":"2000","unstructured":"Flinn IW, Kopecky KJ, Foucar MK, Head D, Bennett JM, Hutchison R, Corbett W, Cassileth P, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum F, Cheson B, Grever MR (2000) Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 96:2981\u20132986","journal-title":"Blood"},{"key":"6173_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1365-2141.2008.07156.x","volume":"142","author":"GM Dores","year":"2008","unstructured":"Dores GM, Matsuno RK, Weisenburger DD, Rosenberg PS, Anderson WF (2008) Hairy cell leukaemia: a heterogeneous disease? Br J Haematol 142:45\u201351. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07156.x","journal-title":"Br J Haematol"},{"key":"6173_CR15","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Du MQ, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, Kumar S, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li XQ, Lim MS, Liu WP, Louissaint A Jr, Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng SB, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L, Xiao W (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia 36:1720\u20131748. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"key":"6173_CR16","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.3390\/ijms24043177","volume":"24","author":"A Ahn","year":"2023","unstructured":"Ahn A, Kim HS, Kim TY, Lee JM, Kang D, Yu H, Lee CY, Kim Y, Eom KS, Kim M (2023) Genetic and clinical characteristics of Korean chronic lymphocytic leukemia patients with high frequencies of MYD88 mutations. Int J Mol Sci 24:3177. https:\/\/doi.org\/10.3390\/ijms24043177","journal-title":"Int J Mol Sci"},{"key":"6173_CR17","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1182\/blood-2006-08-042929","volume":"109","author":"T Robak","year":"2007","unstructured":"Robak T, Jamroziak K, Gora-Tybor J, Blonski JZ, Kasznicki M, Dwilewicz-Trojaczek J, Wiater E, Zdunczyk A, Dybowicz J, Dmoszynska A, Wojtaszko M, Zdziarska B, Calbecka M, Kostyra A, Hellmann A, Lewandowski K, Stella-Holowiecka B, Sulek K, Gawronski K, Skotnicki AB, Nowak W, Zawilska K, Molendowicz-Portala L, Kloczko J, Sokolowski J, Warzocha K, Seferynska I, Ceglarek B, Konopka L (2007) Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood 109:3672\u20133675. https:\/\/doi.org\/10.1182\/blood-2006-08-042929","journal-title":"Blood"},{"key":"6173_CR18","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1080\/10428190903131755","volume":"50","author":"R Zenh\u00e4usern","year":"2009","unstructured":"Zenh\u00e4usern R, Schmitz SF, Solenthaler M, Heim D, Meyer-Monard S, Hess U, Leoncini L, Bargetzi M, Rufener B, Tobler A (2009) Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32\/98. Leuk Lymphoma 50:1501\u20131511. https:\/\/doi.org\/10.1080\/10428190903131755","journal-title":"Leuk Lymphoma"},{"key":"6173_CR19","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/bjh.14207","volume":"175","author":"BM Getta","year":"2016","unstructured":"Getta BM, Woo KM, Devlin S, Park JH, Abdel-Wahab O, Saven A, Rai K, Tallman MS (2016) Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia. Br J Haematol 175:402\u2013409. https:\/\/doi.org\/10.1111\/bjh.14207","journal-title":"Br J Haematol"},{"key":"6173_CR20","doi-asserted-by":"publisher","first-page":"100236","DOI":"10.1016\/j.ctarc.2020.100236","volume":"25","author":"M Wiber","year":"2020","unstructured":"Wiber M, Maitre E, Poncet JM, Duchenet V, Damaj G, Cornet E, Troussard X (2020) A population-based study of hairy cell leukemia over a period of 20 years. Cancer Treat Res Commun 25:100236. https:\/\/doi.org\/10.1016\/j.ctarc.2020.100236","journal-title":"Cancer Treat Res Commun"},{"key":"6173_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41408-020-0328-z","volume":"10","author":"J Paillassa","year":"2020","unstructured":"Paillassa J, Cornet E, Noel S, Tomowiak C, Lepretre S, Vaudaux S, Dupuis J, Devidas A, Joly B, Petitdidier-Lionnet C, Haiat S, Mariette C, Thieblemont C, Decaudin D, Validire-Charpy P, Drenou B, Eisenmann JC, Uribe MO, Olivrie A, Touati M, Lambotte O, Hermine O, Karsenti JM, Feugier P, Vaillant W, Gutnecht J, Lippert E, Huysman F, Ghomari K, Boubaya M, Levy V, Riou J, Damaj G, Tanguy-Schmidt A, Hunault-Berger M, Troussard X (2020) Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up. Blood Cancer J 10:62. https:\/\/doi.org\/10.1038\/s41408-020-0328-z","journal-title":"Blood Cancer J"},{"key":"6173_CR22","first-page":"22","volume":"84","author":"F Lauria","year":"1999","unstructured":"Lauria F, Bocchia M, Marotta G, Raspadori D, Zinzani PL, Rondelli D (1999) Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications. Haematologica 84:22\u201325","journal-title":"Haematologica"},{"key":"6173_CR23","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1200\/JCO.19.02250","volume":"38","author":"D Chihara","year":"2020","unstructured":"Chihara D, Arons E, Stetler-Stevenson M, Yuan CM, Wang HW, Zhou H, Raffeld M, Xi L, Steinberg SM, Feurtado J, James L, Wilson W, Braylan RC, Calvo KR, Maric I, Dulau-Florea A, Kreitman RJ (2020) Randomized Phase II study of first-line cladribine with concurrent or delayed Rituximab in patients with hairy cell leukemia. J Clin Oncol 38:1527\u20131538. https:\/\/doi.org\/10.1200\/JCO.19.02250","journal-title":"J Clin Oncol"},{"key":"6173_CR24","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/bjh.14129","volume":"174","author":"D Chihara","year":"2016","unstructured":"Chihara D, Kantarjian H, O\u2019Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Poku R, Jain P, Thompson P, Brandt M, Luthra R, Burger J, Keating M, Ravandi F (2016) Long-term durable remission by cladribine followed by Rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol 174:760\u2013766. https:\/\/doi.org\/10.1111\/bjh.14129","journal-title":"Br J Haematol"},{"key":"6173_CR25","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1177\/1060028019836775","volume":"53","author":"AC King","year":"2019","unstructured":"King AC, Kabel CC, Pappacena JJ, Stump SE, Daley RJ (2019) No loose ends: a review of the pharmacotherapy of hairy cell and hairy cell leukemia variant. Ann Pharmacother 53:922\u2013932","journal-title":"Ann Pharmacother"},{"key":"6173_CR26","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.2147\/OTT.S242247","volume":"14","author":"Q Liu","year":"2021","unstructured":"Liu Q, Harris N, Epperla N, Andritsos LA (2021) Current and emerging therapeutic options for hairy cell leukemia variant. Onco Targets Ther 14:1797\u20131805","journal-title":"Onco Targets Ther"},{"key":"6173_CR27","doi-asserted-by":"publisher","first-page":"106522","DOI":"10.1016\/j.leukres.2021.106522","volume":"102","author":"JE Moore","year":"2021","unstructured":"Moore JE, Delibert K, Baran AM, Evans AG, Liesveld JL, Zent CS (2021) Targeted therapy for treatment of patients with classical hairy cell leukemia. Leuk Res 102:106522. https:\/\/doi.org\/10.1016\/j.leukres.2021.106522","journal-title":"Leuk Res"},{"key":"6173_CR28","first-page":"152","volume":"82","author":"PL Zinzani","year":"1997","unstructured":"Zinzani PL, Lauria F, Salvucci M, Rondelli D, Raspadori D, Bendandi M, Magagnoli M, Tura S (1997) Hairy-cell leukemia and alpha-interferon treatment: long-term responders. Haematologica 82:152\u2013155","journal-title":"Haematologica"},{"key":"6173_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.clml.2012.06.009","volume":"13","author":"N Daver","year":"2013","unstructured":"Daver N, Nazha A, Kantarjian HM, Haltom R, Ravandi F (2013) Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options. Clin Lymphoma Myeloma Leuk 13:86\u201389. https:\/\/doi.org\/10.1016\/j.clml.2012.06.009","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6173_CR30","doi-asserted-by":"publisher","first-page":"6313","DOI":"10.1158\/1078-0432.CCR-13-1848","volume":"19","author":"M Burotto","year":"2013","unstructured":"Burotto M, Stetler-Stevenson M, Arons E, Zhou H, Wilson W, Kreitman RJ (2013) Bendamustine and Rituximab in relapsed and refractory hairy cell leukemia. Clin Cancer Res 19:6313\u20136321. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1848","journal-title":"Clin Cancer Res"},{"key":"6173_CR31","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa2031298","volume":"384","author":"E Tiacci","year":"2021","unstructured":"Tiacci E, De Carolis L, Simonetti E, Capponi M, Ambrosetti A, Lucia E, Antolino A, Pulsoni A, Ferrari S, Zinzani PL, Ascani S, Perriello VM, Rigacci L, Gaidano G, Della Seta R, Frattarelli N, Falcucci P, Fo\u00e0 R, Visani G, Zaja F, Falini B (2021) Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. N Engl J Med 384:1810\u20131823. https:\/\/doi.org\/10.1056\/NEJMoa2031298","journal-title":"N Engl J Med"},{"key":"6173_CR32","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1056\/NEJMoa1506583","volume":"373","author":"E Tiacci","year":"2015","unstructured":"Tiacci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S, Zaja F, Devlin S, Pulsoni A, Chung YR, Cimminiello M, Kim E, Rossi D, Stone RM, Motta G, Saven A, Varettoni M, Altman JK, Anastasia A, Grever MR, Ambrosetti A, Rai KR, Fraticelli V, Lacouture ME, Carella AM, Levine RL, Leoni P, Rambaldi A, Falzetti F, Ascani S, Capponi M, Martelli MP, Park CY, Pileri SA, Rosen N, Fo\u00e0 R, Berger MF, Zinzani PL, Abdel-Wahab O, Falini B, Tallman MS (2015) Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med 373:1733\u20131747. https:\/\/doi.org\/10.1056\/NEJMoa1506583","journal-title":"N Engl J Med"},{"key":"6173_CR33","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1182\/blood.2020009688","volume":"137","author":"KA Rogers","year":"2021","unstructured":"Rogers KA, Andritsos LA, Wei L, McLaughlin EM, Ruppert AS, Anghelina M, Blachly JS, Call T, Chihara D, Dauki A, Guo L, Ivy SP, James LR, Jones D, Kreitman RJ, Lozanski G, Lucas DM, Ngankeu A, Phelps M, Ravandi F, Schiffer CA, Carson WE, Jones JA, Grever MR (2021) Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. Blood 137:3473\u20133483. https:\/\/doi.org\/10.1182\/blood.2020009688","journal-title":"Blood"},{"key":"6173_CR34","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/bjh.12867","volume":"166","author":"M Sivina","year":"2014","unstructured":"Sivina M, Kreitman RJ, Arons E, Ravandi F, Burger JA (2014) The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. Br J Haematol 166:177\u2013188. https:\/\/doi.org\/10.1111\/bjh.12867","journal-title":"Br J Haematol"},{"key":"6173_CR35","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.3324\/haematol.2022.281754","volume":"108","author":"D Chihara","year":"2023","unstructured":"Chihara D, Gras L, Zinger N, Kr\u00f6ger N, Mayer J, Passweg J, De Latour RP, Byrne J, Kr\u00fcger W, Bohn JP, Platzbecker U, Blau IW, Bonifazi F, Helbig G, McDonald A, Mistrik M, Mohty M, Ram R, Sanz J, Llamas CV, Kreitman RJ, Hayden PJ, McLornan D, Tournilhac O, Van Gelder M, Yakoub-Agha I (2023) Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience. Haematologica 108:1676\u20131679. https:\/\/doi.org\/10.3324\/haematol.2022.281754","journal-title":"Haematologica"},{"key":"6173_CR36","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1182\/blood.2022016183","volume":"140","author":"S Handa","year":"2022","unstructured":"Handa S, Lee JO, Derkach A, Stone RM, Saven A, Altman JK, Grever MR, Rai KR, Shukla M, Vemuri S, Montoya S, Taylor J, Abdel-Wahab O, Tallman MS, Park JH (2022) Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy. Blood 140:2663\u20132671. https:\/\/doi.org\/10.1182\/blood.2022016183","journal-title":"Blood"},{"key":"6173_CR37","doi-asserted-by":"publisher","unstructured":"Maitre E, Tomowiak C, Lebecque B, Bijou F, Benabed K, Naguib D, Kerneves P, Cornet E, Viailly PJ, Arsham J, Sola B, Jardin F, Troussard X (2022) Deciphering genetic alterations of hairy cell leukemia and hairy cell leukemia-like disorders in 98 patients. Cancers (Basel) 141904. https:\/\/doi.org\/10.3390\/cancers14081904","DOI":"10.3390\/cancers14081904"},{"key":"6173_CR38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/hon.975","volume":"29","author":"F Forconi","year":"2011","unstructured":"Forconi F (2011) Hairy cell leukaemia: biological and clinical overview from immunogenetic insights. Hematol Oncol 29:55\u201366. https:\/\/doi.org\/10.1002\/hon.975","journal-title":"Hematol Oncol"},{"key":"6173_CR39","first-page":"424","volume":"22","author":"HS Park","year":"1979","unstructured":"Park HS, Kim HS, Moon ES, Lee CY, Jung TZ (1979) Leukemic reticulodenotheliosis, 1 case. Korean J Med 22:424\u2013431","journal-title":"Korean J Med"},{"key":"6173_CR40","first-page":"377","volume":"27","author":"SJ Jang","year":"1992","unstructured":"Jang SJ, Yeam YS, Moon DS, Suh CH, Jung TH, Chung CH (1992) A case of hairy cell leukemia. Blood Res 27:377\u2013383","journal-title":"Blood Res"},{"key":"6173_CR41","first-page":"395","volume":"28","author":"HK Yoon","year":"1993","unstructured":"Yoon HK, Park SM, Lee JN, Sohn CH (1993) Hairy cell leukemia. Blood Res 28:395\u2013401","journal-title":"Blood Res"},{"key":"6173_CR42","first-page":"675","volume":"28","author":"JG Chung","year":"1994","unstructured":"Chung JG, Gong GY, Choe GY, Yu ES, Lee IC, Park KC, Kim SH (1994) Hairy cell leukemia, a case report. J Pathol Transl Med 28:675\u2013677","journal-title":"J Pathol Transl Med"},{"key":"6173_CR43","first-page":"351","volume":"31","author":"JH Shin","year":"1996","unstructured":"Shin JH, Kim YS, Lee YY, Choi IY, Him IS (1996) Complete remission of hairy cell leukemia by 2-chlorodeoxyadenosine. Blood Res 31:351\u2013356","journal-title":"Blood Res"},{"key":"6173_CR44","first-page":"287","volume":"37","author":"SW Jeong","year":"2002","unstructured":"Jeong SW, Kim SU, Kim CK, Lee KT, Lee NS, Park SK, Won JH, Baick SH, Hong DS, Park HS, Lee YK, Cho HI (2002) Atypical hairy cell leukemia. Blood Res 37:287\u2013291","journal-title":"Blood Res"},{"key":"6173_CR45","first-page":"292","volume":"37","author":"DY Cheung","year":"2002","unstructured":"Cheung DY, Lee S, Kim YJ, Park YH, Kwok SK, Lee HJ, Kim HJ, Kin DW, Lee JW, Min WS, Kim CC (2002) Report of 3 cases of hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood Res 37:292\u2013296","journal-title":"Blood Res"},{"key":"6173_CR46","first-page":"167","volume":"39","author":"MJ Jang","year":"2004","unstructured":"Jang MJ, Rhyu KH, Chong SY, Oh D, Kang MS (2004) A case of hairy cell leukemia, variant. Blood Res 39:167\u2013171","journal-title":"Blood Res"},{"key":"6173_CR47","doi-asserted-by":"publisher","first-page":"237","DOI":"10.12701\/yujm.2004.21.2.237","volume":"21","author":"YG Kim","year":"2004","unstructured":"Kim YG, Lee SJ, Kim MK, Lee KH, Hyun MS, Cho HS (2004) A case of complete remission of hairy cell leukemia by 2-chlorodeoxyadenosine. J Yeungnam Med Sci 21:237\u2013241","journal-title":"J Yeungnam Med Sci"},{"key":"6173_CR48","first-page":"78","volume":"74","author":"HG Yi","year":"2008","unstructured":"Yi HG, Kim SG, Lee MH, Kim JS, Moon Y, Choi SK, Kim CS (2008) Hairy cell leukemia: a case report. Korean J Med 74:78\u201383","journal-title":"Korean J Med"},{"key":"6173_CR49","doi-asserted-by":"publisher","first-page":"438","DOI":"10.7180\/kmj.2018.33.3.438","volume":"33","author":"JW Lee","year":"2018","unstructured":"Lee JW, Choi YM, Yang JY, Han SM, Kim BS, Nam SH (2018) Fludarabine and Rituximab in relapsed or refractory hairy cell leukemia variant: a case report and review of literature. Kosin Med J 33:438\u2013445. https:\/\/doi.org\/10.7180\/kmj.2018.33.3.438","journal-title":"Kosin Med J"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06173-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06173-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06173-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T11:15:27Z","timestamp":1739358927000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06173-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,4]]},"references-count":49,"alternative-id":["6173"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06173-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,1,4]]},"assertion":[{"value":"9 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board (IRB) and Ethics Committee of the Catholic Medical Center, South Korea (KC24RASI0524) and was conducted according to the Declaration of Helsinki guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Because this research involved minimal risk and could be conducted with a waiver of informed consent, the requirement for obtaining consent from participants did not apply to this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}